Details of the Drug

General Information of Drug (ID: DMU7K86)

Drug Name

AK04

Indication

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Bispecific antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[2]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Actinic keratosis

ICD Disease Classification

EK90.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	DTT	CTLA4	2.73E-01	0.02	0.05

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00308867) Photodynamic Therapy With PD P 506 A or Its Placebo Compared With Cryosurgery for the Treatment of Mild to Moderate Actinic Keratosis. U.S.National Institutes of Health.
2	A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.